Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease

Heart and Vessels

Volumn 24, Issue 4, 2009, Pages 301-307

  Omae, Kiyotsugu ^a,b   Ogawa, Tetsuya ^b   Nitta, Kosaku ^b  

^a Yoshikawa Hospital   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Calcium channel blocker; Chronic kidney disease; Estimated glomerular filtration rate; Proteinuria

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PREDNISOLONE; PROBUCOL;

ADULT; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; CHRONIC DISEASE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 68249152209     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-008-1125-y     Document Type: Article

References (31)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1305
2. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G (1998) Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 53:1209-1216
3. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsue W, Sowers J (2000) National kidney foundation hypertension and diabetes executive committees working group: Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 36:646-661
4. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J (1996) Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18
5. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group (2003) Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition, a patient-level meta-analysis. Ann Intern Med 139:244-252
6. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL (1995) Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123:754-762
7. Swales P, Williams B (2002) Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT(1)-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension. J Renin Angiotensin Aldosterone Syst 3:79-89
8. Sica D (2004) Calcium channel blockers and the kidney. Clin Cornerstone 6:39-52
9. Fogari R, Corradi L, Zoppi A, Lazzari P, Mugellini A, Preti P, Rinaldi A (2007) Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. Am J Hypertens 20:1092-1096
10. Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T (2007) Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: An Amlodipine-to-Benidipine Changeover (ABC) study. Hypertens Res 30:797-806
11. Tsuchihashi T, Ueno M, Tominaga M, Kajioka T, Onaka U, Eto K, Goto K (2005) Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine. Clin Exp Hypertens 27:583-591
12. Norris K, Vaughn C (2003) The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. Expert Rev Cardiovasc Ther 1:51-63
13. Vog TL, Kocks MJ, Navis G (2004) Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Minerva Med 95:395-409
14. Ruggenenti P (2004) Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies. Semin Nephrol 24:158-167
15. Ginsberg JM, Chang BS, Matarese RA, Garella S (1983) Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 309:1543-1546
16. Imai E, Matsuo S, Makino H, Watanabe T, Akizawa T, Nitta K, Iimuro S, Ohashi Y, Hishida A; CKD-JAC Study Group (2008) Chronic Kidney Disease Japan Cohort (CKD-JAC) study: Design and methods. Hypertens Res 31:1101-1107
17. Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T (2003) Role of actions of calcium antagonists on efferent arterioles - with special references to glomerular hypertension. Am J Nephrol 23:229-244
18. 2+ channel subtypes and pharmacology in the kidney. Circ Res 100:342-353
19. 2+ channel (alpha1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol 45:241-246
20. Segura J, Garcia-Donaire JA, Ruilope LM (2005) Calcium channel blockers and renal protection: Insights from the latest clinical trials. J Am Soc Nephrol 16(Suppl 1):S64-S66
21. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288:2421-2431
22. Jerums G, Allen TJ, Campbell DJ (2001) Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 37:890-899
23. Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H (2007) Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 30:621-626
24. Yuan Z, Kishimoto C, Shioji K (2003) Beneficial effects of low-dose benidipine in acute autoimmune myocarditis: Suppressive effects on inflammatory cytokines and inducible nitric oxide synthase. Circ J 67:545-550
25. Tsuda K (2008) Electron paramagnetic response investigation on modulatory effect of benidipine on membrane fluidity of erythrocytes in essential hypertension. Heart Vessels 23:134-139
26. Ozawa Y, Hayashi K, Nagahama T, Fujiwara K, Saruta T (2001) Effect of T-type selective calcium antagonist on renal microcirculation; studies in the isolated perfused hydronephrotic kidney. Hypertension 38:343-347
27. Fujiwara K, Kanno Y, Hayashi K, Takenaka T, Saruta T (1999) Renal effects of efonidipine hydrochloride, a new calcium antagonist, in spontaneously hypertensive rats with glomerular injury. Clin Exp Pharmacol Physiol 26:674-679
28. Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T (2005) The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 101:1-13
29. Shiga T, Yamada Y, Matsuda N, Tanaka T, Urae A, Hashiguchi M, Hagiwara N, Kasanuki H (2007) Influence of cilnidipine or nisoldipine on sympathetic activity in healthy male subjects. Heart Vessels 22:404-409
30. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K (2007) Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Disease (CARTER) Study Investigators: Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 72:1543-1549
31. Zucchelli P, Zuccalá A (1998) Progression of renal failure and hypertensive nephrosclerosis. Kidney Int Suppl 68:S55-S59